Breaking News Instant updates and real-time market news.

LXRX

Lexicon

$16.30

-0.08 (-0.49%)

, SNY

Sanofi

$47.36

-0.2 (-0.42%)

18:04
07/31/17
07/31
18:04
07/31/17
18:04

Lexicon exercises option under pact with Sanofi to co-promote sotagliflozin

Lexicon Pharmaceuticals (LXRX) announced that it has exercised its option under its collaboration and license agreement with Sanofi (SNY) to co-promote sotagliflozin, an investigational oral dual inhibitor of sodium-glucose cotransporters 1 and 2, for the treatment of type 1 diabetes in the U.S. The opt-in decision was based on positive data from three Phase 3 studies, inTandem1, inTandem2, and inTandem3 and is aligned to a planned regulatory filing in the U.S. Sanofi intends to file applications in the first half of 2018 for the EU and U.S. regulatory reviews of sotagliflozin for the treatment of type 1 diabetes, pending the full read out of Phase 3 data.

LXRX

Lexicon

$16.30

-0.08 (-0.49%)

SNY

Sanofi

$47.36

-0.2 (-0.42%)

  • 31

    Jul

  • 01

    Aug

  • 15

    Aug

LXRX Lexicon
$16.30

-0.08 (-0.49%)

03/07/17
SBSH
03/07/17
NO CHANGE
Target $28
SBSH
Buy
Lexicon price target raised to $28 from $24 at Citi
Citi analyst Yigal Nochomovitz raised his price target for Lexicon Pharmaceuticals to $28 saying the company's potential in diabetes remains underappreciated. Management's commentary on sotagliflozin should re-assure investors who remain unconvinced about the T1D thesis, Nochomovitz tells investors in a post-earnings research note. He keeps a Buy rating on Lexicon.
03/01/17
WEDB
03/01/17
NO CHANGE
WEDB
Lexicon price target raised to $38 from $33 at Wedbush
Wedbush analyst Liana Moussatos increased her price target on Lexicon after the FDA approved Lexicon's lead drug, Zermelo, for carcinoid syndrome. The analyst thinks that the company has several additional upcoming positive potential catalysts. She keeps an Outperform rating on the stock.
12/22/16
SBSH
12/22/16
NO CHANGE
Target $24
SBSH
Buy
Citi disagrees with market view on Lexicon Pharmaceuticals
After shares of Lexicon Pharmaceuticals fell 7% yesterday following data from the second Phase 3 testing sotagliflozin in Type 1 diabetes, Citi analyst Yigal Nochomovitz says he disagrees with the market view. Investors are "getting too bogged" down on the safety question, the analyst tells investors in a research note. The data "unambiguously solve a major clinical challenge" in Type 1, which is getting A1c lower without the expense of glycemic excursions and thus more hypos, Nochomovitz writes. He keeps a Buy rating on Lexicon with a $24 price target.
12/21/16
12/21/16
NO CHANGE

Lexicon's sotagliflozin meets primary endpoint in Phase 3 trial for diabetes
Lexicon Pharmaceuticals' pivotal inTandem2 Phase 3 clinical trial of sotagliflozin met its primary endpoint, showing a statistically significant reduction in A1C at 24 weeks in patients with type 1 diabetes on optimized insulin therapy. Top-line results from the Phase 3 study showed that patients treated with sotagliflozin had mean A1C reductions from baseline of 0.39% on 200mg once daily sotagliflozin dose and 0.37% on 400mg once daily sotagliflozin dose as compared to a reduction of 0.03% on placebo after 24 weeks of treatment, meeting the study's primary endpoint. This statistically significant and clinically meaningful improvement in A1C for both doses of sotagliflozin was achieved with a favorable overall safety profile in the study, including rates of severe hypoglycemia similar to placebo and low overall rates of diabetic ketoacidosis.
SNY Sanofi
$47.36

-0.2 (-0.42%)

07/31/17
ADAM
07/31/17
NO CHANGE
Target $522
ADAM
Buy
Dupixent authorization approval rate outweighs Q2 miss, says Canaccord
Regeneron (REGN) partner Sanofi (SNY) reported a "very high" 73%-83% prior authorization approval rate for Dupixent in Q2, which Canaccord analyst John Newman said outweighs the fact that sales for the drug at $30.6M were slightly below the $33M consensus forecast. The analyst, who sees rapid payor acceptance of Dupixent as "much more crucial" than the initial quarterly revenue, keeps a Buy rating and $522 price target on Regeneron shares.
07/31/17
PIPR
07/31/17
NO CHANGE
Target $557
PIPR
Overweight
Regeneron indicated lower after Sanofi earnings report, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff says shares of Regeneron (REGN) are indicated lower after partner Sanofi (SNY) reported Q2 U.S. Dupixent sales of $30M in adults with atopic dermatitis. This was essentially in line with the consensus estimate of $33M, Tenthoff tells investors in a research note. He adds that over 5,100 physicians have prescribed and over 13,000 atopic dermatitis patients have been prescribed Dupixent as of July 26. The analyst views the launch stats as impressive and reiterates an Overweight rating on Regeneron with a $557 price target.
07/14/17
WELS
07/14/17
NO CHANGE
Target $41
WELS
Outperform
Wells says smallpox vaccine deal an 'excellent fit' for Emergent BioSolutions
Wells Fargo analyst David Maris said Emergent BioSolutions' (EBS) deal to acquire the ACAM2000 smallpox vaccine business of Sanofi (SNY) is "an excellent fit" and he is "encouraged" by its ability to identify and make a deal for such a "solid target." Maris keeps an Outperform rating and $41 price target on Emergent BioSolutions.
07/10/17
PIPR
07/10/17
NO CHANGE
Target $126
PIPR
Overweight
Alnylam shares overreacting to ALT elevations in OLE data, says Piper Jaffray
Alnylam (ALNY) and partner Sanofi (SNY) presented new Phase II open-label extension study data on 33 hemophilia patients being treated with fitusiran and reported that eleven patients reported asymptomatic ALT increases, up from three observed in its ASH meeting update, noted Piper Jaffray analyst Edward Tenthoff. However, he thinks the stock is overreacting, as the liver enzyme elevations were asymptomatic and largely reversed within one month, he tells investors. Tenthoff, who also sees the efficacy data as encouraging, reiterates his Overweight rating and $126 price target on Alnylam shares.

TODAY'S FREE FLY STORIES

GOOG

Alphabet

$910.67

-0.31 (-0.03%)

, GOOGL

Alphabet Class A

$926.18

-1.48 (-0.16%)

16:32
08/19/17
08/19
16:32
08/19/17
16:32
Periodicals
Google working on new tools to boost news subscriptions, WSJ reports »

Google is said to be…

GOOG

Alphabet

$910.67

-0.31 (-0.03%)

GOOGL

Alphabet Class A

$926.18

-1.48 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

SRE

Sempra Energy

$116.55

0.76 (0.66%)

, BRK.A

Berkshire Hathaway

$267,377.00

302 (0.11%)

16:27
08/19/17
08/19
16:27
08/19/17
16:27
Periodicals
Sempra Energy is third bidder for Oncor Electric, Bloomberg reports »

Sempra Energy (SRE) is…

SRE

Sempra Energy

$116.55

0.76 (0.66%)

BRK.A

Berkshire Hathaway

$267,377.00

302 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Sep

AAP

Advance Auto Parts

$93.26

0.41 (0.44%)

16:20
08/19/17
08/19
16:20
08/19/17
16:20
Periodicals
Advance Auto Parts hit wall on Q2 results, but turnaround intact, Barron's says »

In a follow up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FL

Foot Locker

$34.38

-13.32 (-27.92%)

, AAP

Advance Auto Parts

$93.26

0.41 (0.44%)

16:13
08/19/17
08/19
16:13
08/19/17
16:13
Periodicals
Retail stocks swings could provide opportunity, Barron's says »

This earnings season,…

FL

Foot Locker

$34.38

-13.32 (-27.92%)

AAP

Advance Auto Parts

$93.26

0.41 (0.44%)

LB

L Brands

$36.20

-1.35 (-3.60%)

URBN

Urban Outfitters

$19.27

0.33 (1.74%)

ROST

Ross Stores

$59.02

5.69 (10.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$32.67

-0.28 (-0.85%)

, BMY

Bristol-Myers

$56.42

-0.35 (-0.62%)

16:05
08/19/17
08/19
16:05
08/19/17
16:05
Periodicals
Pharmaceutical companies not the only ones with healthy dividends, Barron's says »

Most income investors are…

PFE

Pfizer

$32.67

-0.28 (-0.85%)

BMY

Bristol-Myers

$56.42

-0.35 (-0.62%)

CAH

Cardinal Health

$64.38

-0.78 (-1.20%)

PDCO

Patterson Companies

$36.45

-0.31 (-0.84%)

RMD

ResMed

$73.07

0.28 (0.38%)

ABC

AmerisourceBergen

$78.60

-1.34 (-1.68%)

UNH

UnitedHealth

$190.82

-1.88 (-0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

  • 27

    Aug

  • 28

    Aug

  • 06

    Sep

  • 08

    Sep

  • 08

    Sep

  • 11

    Sep

  • 11

    Sep

  • 13

    Sep

  • 18

    Sep

  • 20

    Sep

  • 21

    Sep

  • 24

    Sep

  • 09

    Nov

  • 05

    Mar

GDI

Gardner Denver

$21.97

-0.03 (-0.14%)

, KKR

KKR

$18.14

0.11 (0.61%)

15:54
08/19/17
08/19
15:54
08/19/17
15:54
Periodicals
Gardner Denver integrated strategy beginning to pay off, Barron's says »

Under KKR (KKR), who…

GDI

Gardner Denver

$21.97

-0.03 (-0.14%)

KKR

KKR

$18.14

0.11 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSI

Motorola Solutions

$87.37

0.24 (0.28%)

, T

AT&T

$37.37

-0.23 (-0.61%)

15:47
08/19/17
08/19
15:47
08/19/17
15:47
Periodicals
Public-safety broadband network may supplant Motorola systems, Barron's says »

FirstNet has tapped…

MSI

Motorola Solutions

$87.37

0.24 (0.28%)

T

AT&T

$37.37

-0.23 (-0.61%)

CCI

Crown Castle

$104.12

-0.02 (-0.02%)

SBAC

SBA Communications

$142.90

0.69 (0.49%)

AMT

American Tower

$140.00

0.35 (0.25%)

COMM

CommScope

$33.00

0.16 (0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 06

    Sep

LMT

Lockheed Martin

$299.20

-2.22 (-0.74%)

15:39
08/19/17
08/19
15:39
08/19/17
15:39
Periodicals
Lockheed Martin should benefit from boost in military outlays, Barron's says »

Large-cap defense stocks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

SBUX

Starbucks

$52.70

-0.34 (-0.64%)

15:26
08/19/17
08/19
15:26
08/19/17
15:26
Periodicals
Starbucks could jump 20%, Barron's says »

There were plenty of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 02

    Nov

  • 25

    Jan

MRK

Merck

$61.49

-0.35 (-0.57%)

, INTC

Intel

$35.01

-0.16 (-0.45%)

15:05
08/19/17
08/19
15:05
08/19/17
15:05
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

MRK

Merck

$61.49

-0.35 (-0.57%)

INTC

Intel

$35.01

-0.16 (-0.45%)

UA

Under Armour

$15.64

-0.64 (-3.93%)

UAA

Under Armour

$17.12

-0.69 (-3.87%)

CPB

Campbell Soup

$53.69

-0.27 (-0.50%)

JNJ

Johnson & Johnson

$132.63

-0.41 (-0.31%)

UTX

United Technologies

$115.48

-0.62 (-0.53%)

BX

Blackstone

$31.52

-0.08 (-0.25%)

JPM

JPMorgan

$90.74

0.09 (0.10%)

GM

General Motors

$34.83

-0.17 (-0.49%)

WMT

Wal-Mart

$79.31

-0.39 (-0.49%)

TSLA

Tesla

$347.46

-4.46 (-1.27%)

DIS

Disney

$100.70

-0.68 (-0.67%)

AMZN

Amazon.com

$958.47

-2.1 (-0.22%)

AET

Aetna

$154.45

-1.36 (-0.87%)

ANTM

Anthem

$191.02

-0.94 (-0.49%)

CNC

Centene

$83.49

-0.13 (-0.16%)

CI

Cigna

$177.03

-1 (-0.56%)

HNT

Health Net

HUM

Humana

$247.28

-0.38 (-0.15%)

MOH

Molina Healthcare

$59.63

0.12 (0.20%)

UNH

UnitedHealth

$190.82

-1.88 (-0.98%)

WCG

WellCare

$173.56

-2.2 (-1.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 24

    Aug

  • 26

    Aug

  • 28

    Aug

  • 29

    Aug

  • 31

    Aug

  • 05

    Sep

  • 06

    Sep

  • 07

    Sep

  • 08

    Sep

  • 11

    Sep

  • 12

    Sep

  • 22

    Sep

  • 22

    Sep

  • 26

    Sep

  • 27

    Sep

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

  • 12

    Oct

  • 08

    Nov

  • 16

    Nov

  • 20

    Feb

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

CTL

CenturyLink

$19.16

-0.22 (-1.14%)

, LVLT

Level 3

$52.69

-0.3 (-0.57%)

14:52
08/19/17
08/19
14:52
08/19/17
14:52
Hot Stocks
CenturyLink continues to expect acquisition of Level 3 to be complete by Q3 »

CenturyLink (CTL) said in…

CTL

CenturyLink

$19.16

-0.22 (-1.14%)

LVLT

Level 3

$52.69

-0.3 (-0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSU

Kansas City Southern

$105.80

-0.07 (-0.07%)

17:45
08/18/17
08/18
17:45
08/18/17
17:45
Hot Stocks
Kansas City Southern director Henry Maier buys 3,000 shares »

Kansas City Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

RXII

RXi Pharmaceuticals

$0.58

-0.02 (-3.36%)

17:27
08/18/17
08/18
17:27
08/18/17
17:27
Syndicate
Breaking Syndicate news story on RXi Pharmaceuticals »

RXi Pharmaceuticals files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

WIN

Windstream

$1.98

0.06 (3.13%)

17:27
08/18/17
08/18
17:27
08/18/17
17:27
Hot Stocks
Windstream CEO acquires 25,381 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$2.44

-0.22 (-8.27%)

17:27
08/18/17
08/18
17:27
08/18/17
17:27
Syndicate
Breaking Syndicate news story on CEL-SCI »

CEL-SCI files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRN

Trinity Industries

$28.20

-0.03 (-0.11%)

17:25
08/18/17
08/18
17:25
08/18/17
17:25
Hot Stocks
ValueAct raises stake inTrinity Industries to 11% from 9.8% »

As of this date, ValueAct…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPTN

Lpath

17:11
08/18/17
08/18
17:11
08/18/17
17:11
Hot Stocks
Breaking Hot Stocks news story on Lpath »

Stonepine Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PGR

Progressive

$48.63

0.12 (0.25%)

17:08
08/18/17
08/18
17:08
08/18/17
17:08
Hot Stocks
Progressive CFO sells 50,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMO

Thermo Fisher

$172.57

-0.32 (-0.19%)

17:06
08/18/17
08/18
17:06
08/18/17
17:06
Hot Stocks
Thermo Fisher director sells 11,318 shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

SMBC

Southern Missouri Bancorp

$31.18

-0.05 (-0.16%)

17:06
08/18/17
08/18
17:06
08/18/17
17:06
Hot Stocks
Southern Missouri Bancorp and Southern Missouri Bancshares to merge »

Southern Missouri Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:58
08/18/17
08/18
16:58
08/18/17
16:58
Hot Stocks
Breaking Hot Stocks news story on Icahn Enterprises »

Icahn says ended advisory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:57
08/18/17
08/18
16:57
08/18/17
16:57
Hot Stocks
Breaking Hot Stocks news story on Icahn Enterprises »

Icahn says ending…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:57
08/18/17
08/18
16:57
08/18/17
16:57
Hot Stocks
Breaking Hot Stocks news story on Icahn Enterprises »

Icahn says never had…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:56
08/18/17
08/18
16:56
08/18/17
16:56
Hot Stocks
Icahn no longer special advisor to President Trump on regulatory reform issues »

Carl Icahn, founder of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVTA

Invitae

$9.60

0.05 (0.52%)

16:55
08/18/17
08/18
16:55
08/18/17
16:55
Syndicate
Breaking Syndicate news story on Invitae »

Invitae files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.